Yau T.Kang Y.-K.Kim T.-Y.El-Khoueiry A.B.Santoro A.Sangro B.Melero I.Kudo M.Hou M.-M.Matilla A.Tovoli F.Knox J.J.Ruth He A.El-Rayes B.F.Acosta-Rivera M.Lim H.-Y.Neely J.Shen Y.Wisniewski T.Anderson J.CHIUN HSU2022-08-192022-08-1920202374-2437https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092634324&doi=10.1001%2fjamaoncol.2020.4564&partnerID=40&md5=7a59dae69ea45f2bd7e1b77cbbed7295https://scholars.lib.ntu.edu.tw/handle/123456789/617112[SDGs]SDG3Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trialconference paper10.1001/jamaoncol.2020.4564330011352-s2.0-85092634324